Leah Lawrence

GU Oncology Now

The use of neoadjuvant platinum-based chemotherapy (NPAC) was effective for the treatment of metastatic penile squamous cell carcinoma (PSCC), according to data from an international, real-world study presented at ESMO Congress 2022.Jad Chahoud, MD, MPH, of Moffitt Cancer Center, Tampa, Fla., presented this data from what he said was the largest conglomeration of multi-institutional patients with PSCC treated with systemic chemotherapy.&ldquo;Neoadjuvant chemotherapy followed by conservative surgery is supported by the NCCN guidelines and AAU&nbsp; guidelines for patients with bulky fixed or bilateral inguinal lymph node disease, but the evidence supporting these recommendations are lacking and limited by the small sample size and short follow-up of single-center non-randomized clinical trials,&rdquo; Chahoud said. &ldquo;Our study aimed to provide further evidence to support the role of neoadjuvant chemotherapy in locally advanced penile cancer.&rdquo;The study included 167 patients with locally advanced disease enrolled from eight tertiary care centers. All had undergone NAPC prior to surgical resection. The majority (82%) received paclitaxel/ifosfamide/cisplatin.About three-quarters of patients underwent penile-sparing surgical procedures, and the remainder had a radical penectomy. The majority also underwent inguinal lymphadenectomy.The overall response rate was 58%. Serial imaging after NPAC showed that 22% of patients had progressive disease, 20% had stable disease, 47% had partial response, and 11% had a complete response to treatment.Median overall survival was around 47 months and median progression-free survival was around 22 months. Overall survival was significantly improved in patients with complete or partial response with median overall survival of 119 months and 56 months, respectively.Progressive disease was a significant predictor for overall survival included (hazard ratio=2.1; P=.02).&ldquo;The study highlights and shows the clinical safety and efficacy of NDAC in a large cohort of locally advanced penile cancer patients with a large follow-up,&rdquo; Chahoud said.&nbsp;ReferenceESMO Congress 2022 &ndash; 1310MO &ndash; Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study

Neoadjuvant Platinum-Based Chemotherapy Effective for Metastatic Penile SCC

European Society for Medical Oncology Congress 2022

ESMO 2022

Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.

NAT Platinum-Based Chemo for Metastatic Penile SCC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe